Arvinas to present ARV-102 Parkinson's trial data at MDS congress
Tweet Send to a Friend
Arvinas, Inc. (Nasdaq: ARVN) said it will present biomarker data from a Phase 1 clinical trial of its investigational drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




